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Summary
Two classes of adhesion molecules have well-defined roles in the attachment of unstimulated
polymorphonuclear leukocytes(PMN) to cytokine-treated endothelial cells. Endothelial-leukocyte
adhesion molecule 1(ELAM-1) on endothelial cells interacts with specific carbohydrate residues
on the PMN, and the leukocyte integrins (CD18 antigens) on PMN interact with intracellular
adhesion molecule 1 and other structures on endothelium . Here we show that these two classes
of molecules can act sequentially in an "adhesion cascade". Interaction of PMN with SLAM-1-
bearing endothelial cells causes PMN to express enhanced adhesive activity of the integrin CR3
(CD11b/CD18) . Expression ofELAM-1 on the cytokine-treated endothelium appears both necessary
and sufficient for the stimulation ofCR3 activity since blockade ofELAM-1 with mAbs prevents
the activation ofCR3 by cytokine-treated endothelium, and immobilized recombinant ELAM-1
activates CR3 . The ability to activateCR3 is shared by chemattractants, suggesting that ELAM-1
may serve as a "tethered chemattractants" This hypothesis is strengthened by the observation
that recombinant soluble ELAM-1 directs movement of PMN in chemotaxis chambers. These
results suggest a mechanism by which multiple adhesive molecules may function together in
diapedesis. ELAM-1 serves both as an adhesin and as a trigger that recruits the participation
of additional adhesion molecules. Our results also suggest that ligands for adhesion molecules
may also be "receptors" capable of generating intracellular signals.
S
everal classes of molecules have been described that may
serve to directPMN from the blood to sites ofinflamma-
tion in tissues . Brief (5 min) stimulation of endothelial cells
(EC)t with inflammatory molecules such as PMA or
thrombin causes the expression of platelet activating factor
(PAP) (1) and GMP140 (also known as PADGEM ; reference
2) on the endothelial surface. Both of these molecules can
serve as adhesins for PMN (3, 4) . Longer incubation (3 h)
ofEC with inflammatory cytokines such asHA orTNF causes
expression of endothelial-leukocyte adhesion molecule 1
(ELAM-1) (5), a lectin-like molecule (6) that mediates at-
tachment of PMN by binding to SL- carbohydrate-related
structures present on the surface ofPMN (7-9) . Treatment
ofEC with cytokines in thisway causes dramatically enhanced
binding ofPMN in vitro (5, 10) . ELAM-1, GMP-140, and
PAP may serve in the crucial first step of diapedesis, attach-
ment to endothelium .
1 Abbreviations used in this paper. EC, endothelial cells ; ELAM-1, endo-
thelial-leukocyte adhesion molecule 1 ; fNLLP, formyl-norleucyl-leucyl-
phenylalanine; ICAM-1, intracellular adhesion molecule 1; LAD, leukocyte
adhesion deficiency; PAP, platelet activating factor.
PMN also express molecules actively involved in binding
to endothelium, but since cells in the flowing blood are only
briefly in the vicinity of an inflammatory focus, specialized
means are necessary for regulating their adhesive activity. The
leukocyte integrins ((32 integrins, CD18 antigens) are expressed
on the surface ofPMN in an inactive form (11) . Upon stimu-
lation ofthe cells with chemattractants, these receptors tran-
siently acquire adhesive activity, then revert to an inactive
state (11, 12) . Leukocyte integrins may function in multiple,
successive cycles ofadhesion, and we have proposed that the
cycles ofadhesion and release enable locomotion of cells with
adhesion occurring at the leading front of the cell and release
occurring at the uropod (13) . The leukocyte integrin LFA-1
(CQ82, CD11a/CD18) binds to intracellular adhesion mole-
cule (ICAM) on endothelial cells (14, 15), and CR3 (UMR2,
CD11b/CD18, Mac-1) binds to uncharacterized structures on
endothelium (15) .
The leukocyte integrins play a vital role in movement of
cells to inflammatory sites. Binding of chemattractant-
stimulatedPMN to endothelium in vitro is completely blocked
by anti-CD18 mAbs (12, 14, 16) and is nearly absent inPMN
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sion deficiency [LAD]; reference 17). Additional studies in-
dicate thatCD18 molecules are crucial formovement ofPMN
through an endothelial monolayer. Transmigration ofPMN
in vitro is completely blockedby anti-CD18 mAbs (14) . Anti-
CD18 mAbs also completely block the movement ofPMN
to inflammatory sites in the skin (18, 19), brain (20), and
peritoneal cavity (21) of animals, and movement of PMN to
sites ofinflammation is virtually absent in patients withLAD.
The above observations raise question regarding how sev-
eral apparently redundant receptor systems work together to
mediatemovement of cells. In principle, thereceptors could
act in parallel, with each type of adhesion molecule adding
a partial contribution to the adhesive strength needed for
binding. Alternatively, they could act in series, with oneadhe-
sion molecule acting first andenabling or inducing thefunc-
tion of the second . Here we provide evidence supporting a
sequential model. Interaction of unstimulated PMN with
ELAM-1 on endothelial cells or with purified recombinant
ELAM-1 on a culture surface activates the adhesive activity
ofCR3, whichmaythen participate in subsequent adhesion
events . We further show that soluble ELAM-1 serves as a
chemattractant .
Materials and Methods
Reagents.
￿
Glycophorin A, formyl-norleucyl-leucyl-phenylalanine
(fNLLP), PMA, and aprotinin were obtained from SigmaChem-
icalCo. (St . Louis, MO), fibronectin was from theNewYork Blood
Center, andhuman serumalbuminwas from Armour Pharmaceu-
ticals (Kankakee, IL) . EC were stimulated with Re 595 LPS from
List Biologicals (Campbell, CA). Experiments with LPS-coated
erythrocytes used the LPS precursor, lipid IVA, a generous gift of
Dr. C.R .H. Raetz (Rahway, NJ) . Dulbecoo's PBSandPBS deficient
in divalent cations (PD) was from Whitaker MA Bioproducts
(Walkersville, MD). Recombinant TNF-awas a gift ofGenentech,
andrecombinant 11,10was fromR&D Systems (Minneapolis,MN).
Production and characterization of recombinant soluble (rs)
ELAM-1 is described elsewhere (21a). Briefly, insertion of a stop
codon at residue THR531 (6) generated a construct, designated
rsELAM1, lacking putative transmembrane and cytoplasmic do-
mains (6, 22) . After stable expression in CHO cells according to
standard techniques (23), rsELAM1 was purified to homogeneity
from CHO cell-conditioned medium by immunoaffinity chroma-
tography usingmAb BB11 (24) . rsELAM, when immobilized on
plastic, is functional as an adhesive protein, and selectively binds
only cell types known to bind to ELAM-1 on the surface ofEC.
These cells include PMN, HL60, and HT29 (21a) .
Monoclonal Antibodies. mAbs OKM9 and OKM10 directed
against CD11b (25) were a gift of Ortho Pharmaceuticals (Rar-
itan, NJ), mAb LB-2 directed against ICAM-1 (26) was a gift of
Dr. E. Clark (Seattle,WA), mAb H18/7 directed againstELAM-1
(5)wasa gift ofDr.M. Bevilacqua (Boston, MA), mAb3G8 directed
against FcRIII (CD16) was as described (27), andmAb W6/32
against class I histocompatibility antigens wasfrom theAmerican
Type Culture Collection (Rockville, MD). mAb BB11 directed
against ELAM-1 was as described (24) . All antibodies were puri-
fied IgGs .
Cells.
￿
HumanPMN were isolated from adult blood on Ficoll-
Hypaque gradients (28) . Cells were suspended at 2 x 106/ml in
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the buffer HAP (PBS containing 0.5 mg/ml HSA and 0.3 U/ml
aprotinin) .To allow ready identification ofthePMN on endothelial
monolayers, they were fluorescently labeled with 1,1'-dioctadecyl-
3,3,3,3'-tetramethyl-indocarbocyanine perchlorate as described (12) .
EC were isolated from human umbilical cords and seeded on
fibronectin-coated Terasaki wells at either first or second passage,
as described (12) . Fixed monolayers of EC were obtained by in-
cubating washed, live monolayers in Terasaki plates with 0.25%
glutaraldehyde for5 min at 0°C . Themonolayers were extensively
washed and incubated for 1 h with 50 mM glycine to quench un-
reacted glutaraldehyde .
Sheep erythrocytes were coated with IgG (29), C3bi (30), or
the LPS precursor, lipid IVA (31), as previously described . The
amount ofIgG used to coat erythrocytes was adjusted to give sub-
maximal binding (maximal binding yields an attachment index
>1,200) . Thus, either increases or decreases in binding could be
observed .
Assays.
￿
The binding offluorescently labeled PMN to EC was
as described (12) . Briefly, PMN were incubated with EC for 15
min at 37°C, then unbound cells were removedby vigorous agita-
tion. AdherentPMNwere enumerated by fluorescence microscopy.
Binding of ligand-coated erythrocytes to PMN was measured
as previously described (11) . Monolayers ofPMN were established
on protein-coated surfaces by adding 104 PMN in HAP and in-
cubating for 30 min . Erythrocytes were added to the washed
monolayers and, after an additional 30 min incubation, plates were
washed and theattachment oferythrocytes to PMN was enumer-
ated by microscopy. Briefly, in randomly chosen 40 x microscope
fields, allPMN and all erythrocytes bound to PMN were counted .
At least 50PMN were counted in each of duplicate wells. Results
are expressed as attachment index, thenumber oferythrocytes bound
per 100PMN. While the pattern ofresponses to experimental con-
ditions is extremely consistent, the precise level ofbinding observed
varies considerably from experiment to experiment because ofdonor-
to-donor variability in thePMN and variations in the amount of
ligand per erythrocyte. For this reason, it is seldom possible to av-
erage separate experiments . Results of a single experiment, repre-
sentative of several experiments on different donors, are usually
presented .
To measure the binding of ligand-coated erythrocytes to PMN
adherent to endothelial monolayers, 104 labeledPMN and 5 x 105
erythrocytes were added to each well of a Terasaki plate. Cells were
allowed to settle for 10 min at 0°C, then were warmed to 37°C
for 20 min . The plates were then turned upside down to allow
gravity to remove unbound erythrocytes from the monolayer, and
the plate was gently dipped . This procedure allows retention of
PMNweakly adherent to the endothelium . Attachment oferythro-
cytes to PMN was enumerated as describedabove . In experiments
using antibodies against endothelial antigens, the antibodies (10
ug/ml) were incubated for 30 min with the endothelium then
washed away before the addition of PMN.
Chemotaxis.
￿
Migration of PMN across 2-14m polycarbonate
filters (Nucleopore Corp., Pleasanton, CA) was measured in a
48-well Boyden chamber (Neuroprobe Inc., Cabin John, MD) by
the method of Deuel et al . (32) . The upper wells contained 2.5
x 104 PMN in HAP buffer and the lower chambers contained
chemattractant diluted in HAP buffer. After a 2-h incubation at
37°C, the cells that had migrated through the 2-Itm pores into
an underlying 0.45-p nitrocellulose filter were enumerated by mi-
croscopy. Results are expressed as the number of migrated PMN
observed per 20x field. All conditions were assayed in six replicate
wells .
For observation of the behavior of single cells, glass coverslips
Endothelial-Leukocyte Adhesion Molecule 1 Activates Leukocyte Integrinswere coated with 100 FAg/ml fibrinogen (KabiVitrum) for 60 min,
washed, and a monolayer ofPMN was established on the coated
coverslip by adding 0.25 ml of PMN diluted to 2 x 106/ml in
HAP and incubating for 60 min at 37°C . The coverslip was fitted
into a pre-warmed Zigmond apparatus (Neuroprobe Inc.) containing
HAP buffer on both sides of the chamber. A time lapse video
recording of a 20x field was then made to verify that the cells
were immobile. Recordings were made at 37°C using a Nikon Di-
aphot equipped with temperature-controlled stage . After the ini-
tial recording, chemattractant was added to one side of the chamber
and an additional recording was made for 20 min . Manual tracings
of the paths of individual cells were made from the recorded video
images.
Results
Attachment ofPMN to Cytokine-treated Endothelium Activates
CR3. CR3 recognizes complement protein Obi (25),
fibrinogen (33, 34), and LPS (31), as well as molecules on
endothelium . The binding activity ofCR3may thus be mea-
sured by observing the binding of erythrocytes coated with
C3bi (EC3bi) or LPS (ELPS) to the PMN or by measuring
attachment ofPMN to endothelium. Suspensions of resting
PMN express CR3 that is incapable of binding any of its
known ligands. Thus, the cells fail to bind EC3bi (11) orELPS
(35) and fail to adhere firmly to endothelial cells (12) . CR3
remains inactive whenPMN attach to protein-coated plastic
surfaces since monolayers of PMN fail to recognize EC3bi
(Table 1) (11) . We found that incubation ofPMN with resting
EC also does not affect CR3 activity since the weakly ad-
herentPMN show low binding ofEC3bi similar to that seen
with parallel populations of PMN plated on serum al-
bumin-coated plastic (Table 1) . In contrast, attachment of
PMN to endothelium stimulated with TNF-a, 1140, orLPS
caused a 4-12-fold enhancement of CR3 activity measured
by binding ofEC3bi. The extent of activation was similar
to that observed with fNLLP, a chemattractant known to
strongly activate CR3 . These data suggest that interaction
of PMN with cytokine-treated endothelium results in the
activation of the binding activity of CR3 .
Several experiments indicate that the enhanced binding of
EC3bi caused by adhesion of PMN to cytokine-treated en-
dothelium is the specific result ofincreased activity ofCR3 .
Alterations in nonspecific adhesion of erythrocytes is unlikely
to underlie our results since binding of control IgG-coated
erythrocytes to Fc receptors on PMN was unaffected by the
activation state ofthe endothelium (Table 1) . Previous studies
showed that the binding activity ofCR3 is completely blocked
by removal of divalent cations (29) or by inclusion of the
anti-CR3 mAb OKM10 (25) . We confirmed that both of
these treatments also completely blocked binding ofEC3bi
to PMN adherent to TNF-treated EC (data not shown) . Fi-
nally, enhanced binding of EC3bi requires active metabolism
ofPMN since no binding could be observed in preparations
held at 0°C (data not shown) .
CR3 expresses two distinct binding sites, one for protein-
aceous ligands such as Obi and an additional binding site
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Monolayers of endothelial cells were incubated for 3 h with 10 ng/ml
TNF-a, 50 ng/ml LPS, 5 U/ml IL-1/3, or with medium alone. Control
albumin-coated plastic wells contained no endothelial cells . Wells were
washed and mixtures oferythrocytes, andPMN were added and incubated
as described in Materials and Methods . Attachment of erythrocytes to
adherent PMN was ennumerated and reported here as attachment index,
the number of erythrocytes per 100 PMN . Results of a single experi-
ment, representative of seven separate experiments, are reported.
i fNLLP (10-7 M) was added with the PMN .
that recognizes LPS (36) . The binding activity of both sites
can be strongly enhanced by chemattractants such as NAP
1/11r8 (35) . We found that attachment ofPMN to TNF-
treated EC, but not unstimulated EC, also enhanced the
binding of ELPS (Table 1) . Thus, attachment of PMN to
cytokine-treatedEC activates both of the binding sites ofCR3 .
Previous studies indicate that chemattractants enhance adhe-
sive activity ofCR3 by two mechanisms . Fusion of intracel-
lular membranes with the plasmamembrane results in a two-
to threefold rise in expression of CR3, and simultaneous
qualitative changes cause a 5-10-fold increase in the adhesive
activity of existing CR3 (11, 12, 35, 37, 38) . Preliminary
studies suggest that interaction ofPMN with cytokine-treated
endothelium for 20 min causes an -10% rise in cell surface
CR3 (S.K . Lo and S.D. Wright, unpublished observations)
and thus qualitative changes in existing CR3 may be prin-
cipally responsible for the increased adhesive activity. How-
ever, the precise contribution of newly recruited CR3 is not
established by the current studies.
The time course for the acquisition ofCR3 activating ca-
pacity was explored by incubating monolayers of EC for
different intervals with TNF before fixation and incubation
with PMN (Fig. 1) . Incubation of EC with TNF-a for 15
min caused no increase in the activity of CR3 on adherent
PMN . This observation suggests that TNF is not having its
effect by being "carried over" in the cultures and directly
stimulating the PMN . Rather, TNF must act by inducing
a response in the EC . The EC became capable of activating
PMN after 2 h of exposure to TNF, but activity declined
to control levels by 17 h . Thus, the capacity to activate PMN
is transiently induced by TNF.
Table 1 . Adhesion ofPMN to
Activates CR3
Cytokine-treated Endothelium
Attachment
erythrocytes to
of
PMN"'
Substrate EC3bi ELPS EIgG
Endothelium 18 23 316
Endothelium, fixed 31 ND ND
Endothelium + TNFcx 313 169 339
Endothelium + TNFac, fixed 402 ND ND
Endothelium + LPS 243 78 281
Endothelium + IL-113 320 80 339
Albumin-coated plastic 19 ND 296
Albumin-coated plastic + fNLLP 383 ND NDk
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￿
TNF-a transiently enables endothelial cells to activate CR3
on adherent PMN . EC were incubated for various times with 10 ng/ml
TNF-a, then washed andfixed. Cells were incubated with the monolayers
for 15 min and binding ofPMN to the EC, expressed as cells/mm2, was
determined after a vigorous wash . In parallel wells, a mixture of PMN
and EC3bi was incubated with the EC, and the attachment of erythro-
cytes to PMN was measured as described in Materials and Methods . Results
are representative of two experiments .
In agreement with other studies (39, 40) incubation with
TNF caused enhanced attachment of PMN, and enhanced
attachment was approximately equal from 3 to 17 h of incu-
bation. Since binding ofPMN to EC at 17 h is avidbut binding
ofEC3bi to the PMN is low, it appears that activation of
CR3 is not simply influenced by the extent of adhesion of
PMN to EC .
Anti-ELAMBlocks the Activation ofCR3 by Cytokine-activated
EC. The time course for the acquisition ofCR3-activating
ability differs from the time course of expression o£the adhe-
sion molecule ICAM-1, which remains elevated for >17 h,
but corresponds precisely with that for the expression of
ELAM-1 on EC (41) . To determine ifELAM-1 on the sur-
face ofEC plays a role in the activation ofCR3, monolayers
of TNF-treated EC were incubated withmAbs against a va-
riety ofendothelial surface structures (Fig. 2) . mAbs against
HLA or ICAM-1 had no effect on the activation of CR3
by EC . However, two anti-ELAM mAbs, BB11 and H18/7,
each completely blocked the activation ofCR3 . This obser-
vation suggests that expression ofELAM-1 is necessary for
EC to activate CR3 on PMN .
EC are known to synthesize IL -8 (42) and PAP (1), both
potent activators ofCR3 (35 ; and S.D. Wright, unpublished
observations) . We thus considered the possibility that these
secreted molecules may contribute to the effects ofcytokine-
treated EC on CR3 activity. IL8 is unlikely to play a role
since fixed EC, which cannot secrete, are as active as unfixed
cells in stimulating PMN (Table 1) . Moreover, 1178 produc-
tion byEC is strongly induced after 17 h of incubation with
TNF (43), but EC stimulated in this way do not activate
CR3 (Fig . 1) . PAP binds to the plasma membrane of theEC
and may be retained after fixation (3) . To explore a role for
PAP, the strong PAP antagonist, WEB 2086, was included
in cultures ofPMN and TNF-treated EC. We used concen-
trations ofWEB 2086 (10 j,M) that completely blocked the
ability ofpurifiedPAP to activate CR3 (Hermanowski Vosatka,
c d
L a
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Figure 2 .
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Anti-ELAM-1 blocks the activation ofCR3 by cytokine-treated
endothelium . Endothelial monolayers were treated with medium alone
or 10 ng/ml TNF-a for 3 h at 37°C. 10 Ag/ml of the indicated mAbs
were added followed by PMN anderythrocytes, and attachment ofEC3bi
to PMN was determined as described in Materials and Methods. The con-
trol antibodies, anti-ICAM-1 and anti-HLA, each react strongly with
cytokine-treated EC (43), and our previous results showed that the anti-
ICAM-1 effectively blocks ICAM-1-dependent binding of PMN events
under similar conditions (15) . Results are representative of four separate
experiments .
A., and S.D. Wright, manuscript in preparation) . This an-
tagonist had no effect on the stimulation of CR3 activity
by cytokine-treated endothelium, suggesting that CR3 is not
activated by PAP on the surface of cytokine-treated en-
dothelium .
Purified ELAM Activates CR3 .
￿
We have recently gener-
ated a recombinant soluble form ofELAM-1 lacking the trans-
membrane and cytoplasmic domains (21a) . The protein is a
functional adhesion molecule since surfaces coated with
rsELAM-1 avidly bind neutrophils and H1r60 cells (21a) . To
determine ifELAM-1 is sufficient to activate CR3, we ob-
servedPMN adherent to the immobilized rsELAM-1 . Binding
of PMN to ELAM-1-coated surfaces caused strong activa-
tion of CR3 (Table 2) . In contrast, surfaces coated with
albumin or glycophorin had no effect onCR3 activity. Acti-
vation ofCR3 is unlikely to be caused by nonspecific interac-
tion with an adhesive surface since attachment of PMN to
a substrate coated with mAb 3G8 against the abundant sur-
face glycoprotein, FcyRIII, caused no alteration in CR3
activity (Table 2) . Activation of CR3 is also unlikely to be
caused by contaminants ofELAM-1 such as LPS, since boiled
rsELAM-1 was ineffective in stimulating CR3 activity, and
polymyxin B sulfate, a drug that neutralizes LPS, had no effect
on activation ofCR3 by rsELAM-1 (data not shown) . More-
over, addition ofanti-ELAMmAbs to the coated surface com-
pletely blocked the activationby purifiedELAM-1 (Table 2) .
These experiments indicate that interaction ofELAM-1 with
its counter structures on PMN is sufficient to cause activa-
tion of CR3 .
SolubleELAM-1 Is a ChemattractantforPMN
￿
Allknown
chemattractants ofPMN activateCR3 perhaps because adhe-
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Attachment ofPMN to ELAM-1-coated Surfaces
' Terasaki wells were coated with 10 wg/ml ofglycophorin, HSA, 3G8
(anti-Fc-yRIII), or ELAM-1 for 2 h at 20° C. 5 mg/ml HSA was added
for an additional 1 h, and plates were washed. 10 F+g/ml ofthe indicated
mAbs was added to the substrates for 40 min at 20° C. After a wash,
a monolayer ofPMN was established on the surfaces, EC3bi were added,
and the attachment index was measured as described in Materials and
Methods . The series of experiments in the upper panel shows that anti-
ELAM-1 mAbs block the activation ofPMN caused by surface-bound
ELAM-1 . A separate series ofexperiments in the lower panel shows that
attachment ofPMN to a nonbinding surface (HSA) or a binding surface
(3G8) does not affect CR3 activity on adherent PMN. The day-to-day
variations in levels of binding were relatively small in these experiments,
thus permitting averaging of independent experiments. Results are aver-
aged from three to five separate studies and are presented with SD.
Y fNLLP (10-7 M) was added with the PMN.
sive interactions of CR3 with the substrate at the leading
edge of the cell are needed for locomotion (13) . Our obser-
vations show that ELAM-1 exhibits this characteristic of
chemattractants and suggests that ELAM-1 may serve as a
"tetheredchemattractant" to direct the movement ofPMN.
The availability of a soluble (untethered) form of ELAM-1
allowed us to test this hypothesis . We found that PMN
migrated across microporous filters in response torsELAM-1
(Fig. 3) . The specificity of this response is indicated by the
finding that treatment of the rsELAM-1 with mAb BB11
completely abolished its chemattractant activity. The dose
of rsELAM-1 needed for maximal chemattractant activity
(10- ' M) was similar to the optimal dose of fNLLP assayed
in parallel . Direct comparisons also showed that the magni-
tude of the chemotactic response to rsELAM-1 varied from
equal to one-third the magnitude of response to fNLLP .
The response of PMN to rsELAM-1 was found to be
chemattractant, not merely chemokinetic, by direct observa-
tion in a Zigmond chamber. In the absence of chemattrac-
tant, PMN in the chamber remained round and immobile.
Within 2 min of the introduction of 10 -7 rsELAM-1 into
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rsELAM-1 stimulates movement ofPMN across filters . A
Boyden chamber was assembled as described in Materials and Methods
with the indicated doses of fNLLP or rsELAM-1 in the lower chamber.
Migration in response to 10 -7M rsELAM-1 neutralized with a 10-fold
weight excess of BB11 was 1.0 ± 0.6 cells/field. Endotoxin contamina-
tion of theELAM-1 is unlikely to beresponsible for the results since boiling
theELAM-1 completely eliminated its chemotactic activity, and purified
endotoxin (1 ng/ml) hadno chemotactic activity in the assay . Similarly,
it is unlikely that adsorption of the ELAM-1 to the filters caused hap-
totaxis since the filters are soaked in protein-containing buffer (HAP) be-
fore assembly into the apparatus. Finally, inclusion of 10-7M ELAM-1
in the upper chamber eliminated chemoaaxis to 10 -7M ELAM-1 in the
lower chamber. Results are presented as the number ofmigrated cells per
20 x field ± SD .The experiment shown is representative of nine separate
studies. When no chemoattractant was added, the error bars were smaller
than the symbol (0.33 ± 0.51 cells/field) . t Test statistics comparing
rsELAM-1 with no chemattractant showed that all concentrations of
rsELAM-1 shown here caused a highly significant increase in cell migra-
tion (p < 0.0005) . The decrease in movement observed from 10-7 to
5 x 10 -7 M rsELAM-1 was also significant (p = 0.068) .
one side of the chamber, PMN began to orient and move .
The movement induced by rsELAM-1 was predominantly
in the direction of the source of chemattractant (Fig. 4) .
Directed movement ofPMN toward ELAM-1 was detected
using source concentrations as low as 10-9 M, but rsELAM-1
neutralized with a 10-fold excess oftheanti-ELAM antibody
BB11 showed no chemattractant activity (data not shown) .
ELAM-1 has been described as an adhesion molecule,
bindingPMN to cytokine-treated endothelial cells (5) . Here
we show that ELAM-1 serves a second function . It recruits
theparticipation of an additional class of adhesion molecules,
theleukocyte integrins, in theadhesion event. Theseandother
results suggest that ELAM-1 and theleukocyte integrins may
normallywork in asequence or cascade (Fig. 5) . Under con-
ditionsofflow, ELAM-1 is far more effective thanCD18 mol-
ecules in initiating adhesion betweenPMNandEC (44) . Thus,
at an established site of inflammation, the first binding of
PMN to EC is likely to be mediated byELAM-1. The func-
tion of leukocyte integrins induced by binding to ELAM-1
is essential for the next events, the movement ofPMN to
ajunction between endothelial cells and diapedesis (14, 18).
The sequential nature of the functioning of these molecules
Activates CR3
Attachment of
Substrate mAb EC3bi to PMN"
Glycophorin 66 ± 42
Glycophorin
+ fNLLP2 - 504 ± 103
ELAM-1 - 245 ± 52
ELAM-1 Anti-ICAM-1 375 ± 179
ELAM-1 Anti-HLA 396 ± 134
ELAM-1 Anti-ELAM (131311) 85 ± 24
ELAM-1 Anti-ELAM (H18/7) 63 ± 25
HSA - 88 ± 28
HSA+fNLLP2 - 554 ± 244
mAb 3G8 - 65 ± 55
ELAM-1 - 425 ± 244Figure 4 .
￿
rsELAM-1 stimulates directed movement ofPMN . A Zig-
mond chamber was assembled as described in Materials and Methods with
10 wg/ml rsELAM-1 (10-7 M) in one chamber. The positions of in-
dividualPMN at the beginning ofthe recording are depicted as filled circles,
and their positions after 20 min are depicted as open circles . The lines
trace the path of migration with arrows showing direction of movement
added for clarity. The drawing is oriented such that the chamber con-
taining rsELAM-1 is at the bottom of the page. Cells exhibited no move-
ment before the addition of rsELAM-1, and parallel studies showed no
movement in response to 10 tLg/ml ELAM-1 neutralized with 100 ttg/ml
BB11. Results depict theimage from a single 20x field and are representa-
tive of three separate studies .
may explain why anti-CD18 antibodies completely block
inflammatorymovement ofPMN in animals despite the pres-
ence ofELAM-1, and suggest that anti-ELAM-1 mAbs may
have similar in vivo potency in inflammatory conditions in
which ELAM-1 is present . The adhesion cascade proposed
here resembles in some ways the interaction of cytotoxic T
cells with their targets . The TCR isknown to mediate weak
binding of cytotoxic T cells to targets, and crosslinking of
theTCRmay recruit the participation ofLFA1 to strengthen
adhesion (45) .
The experiments described here may provide a model for
understanding the individual contribution of multiple adhe-
1 . Binding end stimulation
￿
2 . Cycles of adhesion
mediated by ELAM-1
￿
and release mediated
by leukocyte ingrins (CO18)
CR3 (active)
Ci13 (inactive)
LFA-1 (inactive)
C
, .,.(J
￿
FA-1 (active)
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Figure 5 .
￿
Model of the sequential function of ELAM-1 and leukocyte
integrins in the movement ofPMN across endothelial monolayers at a
site of inflammation . See text for details .
sion molecules in complex events such as lymphocytehoming
and in the movements of embryogenesis . The ability of an
adhesion molecule such as ELAM-1 to induce a response in
a neighboring cell also suggests that the ligands for adhesion
molecules may themselves be "receptors" capable of gener-
ating responses in the cells that bear them . Since ELAM-1
initiates strong responses in PMN, we predict that at least
a subset of the glycoproteins recognized byELAM-1 are such
signaling receptors .
Gradients of soluble rsELAM-1 caused directed movement
ofPMN (Figs . 3 and 4) . Chemotaxis is a complex event re-
quiring orientation ofthe cell, increased adhesion at the leading
edge, and vigorous cytoskeletal activity. Thus, the enhanced
activity ofCR3 we observed is likely to represent one ofsev-
eral responses induced by ELAM-1 . The ability ofELAM-1
to serve as a chemattractant suggests that this moleculemay
carry directional information and may explain the observa-
tion that migration of PMN through unstimulated en-
dothelium is dependent on an applied gradient of soluble
chemattractant but that rapid movement ofPMN through
monolayers of cytokine-treated endothelium occurs without
a requirement for such a gradient (46, 47) . Since ELAM-1
is normally observed as a cell-bound molecule, it may serve
as a "tethered chemattractant" to precisely direct the move-
ment of leukocytes. Our observations also suggest that soluble
ELAM-1 may have an effect on leukocytes. Indeed, addition
of solubleELAM-1 to monolayers ofPMN causes enhanced
CR3 activity (S.D. Wright, unpublished observations), and
addition of soluble ELAM-1 to suspensions ofPMN causes
enhanced adhesion to ICAM-1-bearing cells (S.K . Lo andM .
Bevilacqua, manuscript in preparation) . The observation of
a soluble form ofELAM-1 in serum (W Newman, personal
communication) raises the possibility that ELAM-1 could also
serve as a conventional chemattractant upon release from the
cells.
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